Valeant to buy Bausch+Lomb for $8.7 billion
Valeant Pharmaceuticals International Inc. is acquiring Bausch+Lomb Holdings Inc. for $8.7 billion in cash. With the deal, announced on Monday, Bausch+Lomb will retain its name and become a division of Valeant.